Articolul precedent |
Articolul urmator |
653 17 |
Ultima descărcare din IBN: 2022-12-22 19:33 |
SM ISO690:2012 SÎRBU, Inesa, DIUG, Eugen, CIOBANU, Nicolae, GURANDA, Diana, CIOBANU, Cristina, ANTON, Mihail. New technologies in the development of anti-COVID-19 vaccines. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 442. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 442-442 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. The COVID-19 pandemic as presented unique challenges for the development of modern technologies for large-scale vaccine production. Such an urgent need for a new vaccine has led to a significant reduction in the time required for research. Objective of the study. Description of new directions for accelerating the development of anti-COVID vaccine technologies with high stability and immunogenicity. Material and Methods. The main sources of information on the results of research on vaccine types and their manufacturing platforms were selected. Results. Conventional vaccine technologies are based on viral vectors such as: Oxford Astra-Zeneca; Johnson&Johnson; Gam-COVID-Vac Gamaleia, or Sinopharm (SARS-coV-2 inactivated virus). Unlike these technologies, a new direction for the development of anti-COVID-19 vaccines are non-viral ones, based on synthetic nanoparticles that encapsulate nucleic acids (DNA, RNA). BioNTech/Pfizer and Moderna developed both COVID-19 mRNA vaccines using lipid-based nanoparticles, which demonstrated 94-95% efficacy in clinical trials. Vaccines based on polymeric, non-metallic and metallic nanoparticles are at different stages of development. Conclusion. The non-viral COVID-19 vaccine platforms (DNA and mRNA) were selected from among the first candidates to enter the clinical trial, for safety reasons and a relative manufacturing facility. New nanotechnologies are also promising in the treatment of other viral infections. |
||||||
Cuvinte-cheie nanotechnologies, vaccines, COVID-19, nanotehnologii, vaccinuri, COVID-19 |
||||||
|